Biotech entrepreneur #Oncology#Immunology- BiPER Therapeutics CEO & Co-Founder First In Class therapeutics to treat GI Cancers - G.CLIPS Biotech Board Member
@BowTiedBiotech Indeed this is the solution and it exist for real ! Check G.CLIPS enabling technology https://t.co/piQUPT6IbC we are able to produce stabilized membrane proteins in the desired conformation and to perform the pharmacological profiling of NCEs mAbs and CARs 😉
BiPER Therapeutics is committed to the fight against cancer / BiPER Therapeutics est engage dans la luttte contre le cancer Let s fight together ! #WorldCancerDay#CloseTheCareGap
What a great start of 2024! Excited, happy and proud to share our latest work published today #openaccess@NatureMedicine on the PANDA trial: neoadjuvant atezo+chemo in pts with gastric/GEJ cancers followed by surgery. Some of the key findings below. 1/10 https://t.co/ApfPdsYu2f
GI cancers are the main cause of cancer-related deaths worldwide including 1/3 of deaths related to cancers. Yet research is underfunded and hospital staff is underrepresented.
GRP78 is a promising new pan-cancer target for CAR-T therapy (but with a twist). Great preclinical study by @Jorge88382322 @GiedreKrenciute @PaulinaV_MD and the St Jude team https://t.co/OerzVlEB05
'BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist'
https://t.co/QuDXCBGklU
My husband and I share our views on #BRAFV600E#CRC as a #patient and a #caregiver with the expert Christelle de la Fouchardière
New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer https://t.co/sJKxuVlo6L @VanMorrisMD@mdmanishshah@DrRonanKelly
At @ASCO, @BeiGeneGlobal presented positive results from their phase 3 study of tislelizumab plus chemotherapy as a first-line treatment of advanced gastric cancer that demonstrated meaningful improvement in overall survival. https://t.co/wrCy2FCaqn
BiPER Therapeutics fait partie de le selection @Challenges des 100 start ups ou #investir. Notre candidat medicament a une approche unique pour traiter les patients atteints de #Cancers gastrointestinaux https://t.co/mZAyyCkTPy